CN102302564B - Pain stasis and paralysis eliminating powder for treating soft tissue injury - Google Patents
Pain stasis and paralysis eliminating powder for treating soft tissue injury Download PDFInfo
- Publication number
- CN102302564B CN102302564B CN 201110273415 CN201110273415A CN102302564B CN 102302564 B CN102302564 B CN 102302564B CN 201110273415 CN201110273415 CN 201110273415 CN 201110273415 A CN201110273415 A CN 201110273415A CN 102302564 B CN102302564 B CN 102302564B
- Authority
- CN
- China
- Prior art keywords
- parts
- grieved
- blood stasis
- arthralgia due
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 46
- 230000036407 pain Effects 0.000 title claims abstract description 46
- 208000026137 Soft tissue injury Diseases 0.000 title claims abstract description 27
- 239000000843 powder Substances 0.000 title abstract description 10
- 206010033799 Paralysis Diseases 0.000 title abstract 8
- 210000004369 blood Anatomy 0.000 claims abstract description 112
- 239000008280 blood Substances 0.000 claims abstract description 112
- 239000003814 drug Substances 0.000 claims abstract description 41
- 230000008961 swelling Effects 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 26
- 230000001154 acute effect Effects 0.000 claims abstract description 16
- 239000004863 Frankincense Substances 0.000 claims abstract description 9
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 206010024453 Ligament sprain Diseases 0.000 claims abstract description 5
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims abstract description 4
- 208000026843 stiff neck Diseases 0.000 claims abstract description 4
- 208000006820 Arthralgia Diseases 0.000 claims description 80
- 238000011282 treatment Methods 0.000 claims description 58
- 206010042674 Swelling Diseases 0.000 claims description 31
- 241000717739 Boswellia sacra Species 0.000 claims description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 20
- 241000180649 Panax notoginseng Species 0.000 claims description 20
- 241000334161 Cercis chinensis Species 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 14
- 241001057584 Myrrha Species 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 32
- 238000012360 testing method Methods 0.000 abstract description 6
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241001506304 Kadsura japonica Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 229960001259 diclofenac Drugs 0.000 description 26
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 21
- 230000000399 orthopedic effect Effects 0.000 description 20
- 239000011505 plaster Substances 0.000 description 20
- 239000002674 ointment Substances 0.000 description 19
- 206010014080 Ecchymosis Diseases 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 230000037230 mobility Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000017531 blood circulation Effects 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 8
- 239000002655 kraft paper Substances 0.000 description 8
- 235000011837 pasties Nutrition 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010018852 Haematoma Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical class C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 241000131329 Carabidae Species 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to pain stasis and paralysis eliminating powder for treating soft tissue injury. The pain stasis and paralysis eliminating powder is mainly prepared from the following raw material drugs in parts by weight: 400 to 600 parts of rhubarb, 400 to 600 parts of frankincense, 400 to 600 parts of pseudo-ginseng, 725 to 925 parts of kadsura rootbark, and 650 to 850 parts of angelica.The invention also provides application of the pain stasis and paralysis eliminating powder for treating soft tissue injury. The pain stasis and paralysis eliminating powder has the advantages that: the pain stasis and paralysis eliminating power is compatible with a principle of Chinese medicament 'monarch, minister, assistant and guide'; and pharmacodynamic tests prove that the pain stasis and paralysis eliminating powder has the remarkable effects of activating blood and eliminating stasis, and reducing swelling and relieving pain. The powder is used for treating pains and swelling caused by acute and chronic soft tissue injuries, lumbar sprain, stiff neck and gonarthromeningitis, has small toxic or side effect, remarkable curative effect, low cost and is safe to administer convenient to manufacture, suitable for long-term use and easy for wide popularization, and thus the pain stasis and paralysis eliminating powder is a safe and effective external medicament for treating acute and chronic soft tissue injuries.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, specifically, is that a kind of grieved arthralgia due to blood stasis for the treatment of soft tissue injury looses and application.
Background technology
Acute soft tissue injury is common clinical, frequently-occurring disease, the soft tissues such as skin, subcutaneous tissue, muscle, tendon, fascia, ligament, joint capsule, synovial membrane capsule, intervertebral disc, peripheral nerve and blood vessel that refer to human body are subjected to the violence bump, brute force is reversed, caused damages such as tractive compressing, but do not have fracture or dislocation.Soft tissue is subjected to the effect of external different causative factors of injury, surpasses soft tissue and can bear load when stress reaches certain intensity, causes the temporary transient disorder of the acute destruction of tissue morphology and tissue physiology's function and brings out damage, produces symptom.Clinical manifestation is local pain, tenderness, swelling, livid purple ecchymosis, limb activity dysfunction etc.
The main pathological change of acute soft tissue injury is principal character with local acute injury inflammation and tissue repair.Acute soft tissue injury local organization pathological change mainly shows as aseptic inflammation, positive, the complicated stress that to be body take place harmful factor, its change substantially be ooze out, necrosis and hypertrophy.Because the hemorrhage formation hematoma of the damage local capillary rupture in back, capillary permeability raises, and tissue fluid is outer in a large number to be seeped into interstice, and swelling, blood stasis appear in local organization.Swelling causes that local organization protectiveness spasm and wounded tissue damage pain in various degree then makes body generation dysfunction.This process causes the histiocyte necrosis, local little angiorrhexis, the stimulation blood vessel generation spasm of hemorrhage, blood stasis and causative factors of injury is destroyed local blood circulation, causes variation such as regional blood flow, blood flow rate, whole blood viscosity, blood plasma viscosity simultaneously and makes abnormal hemodynamics.In the process of inflammation, also there is multiple inflammatory mediator, they can act on local vascular alone or synergistically, and to strengthen vascular permeability, in these media, what play an important role has 5-hydroxy tryptamine (5-HT), a prostaglandin (P part E2) etc.
Acute soft tissue injury belongs to the category of " muscle and tendon injury " in orthopedics and traumatology of Chinese medicine is dialectical, " Yizong Jinjian bonesetting heart method main idea " record: " traumatic injury, blood stasis stagnates, swollen hard myospasm ".The main clinical manifestation that soft tissue injury is described is pain, swelling, dysfunction." element is asked, the big opinion of YIN YANG classification of natural phenomena " points out " impairment of QI resulting in pain, injury of configuration resulting in swelling ".Point out to damage local pain, swelling is the main disease performance of acute soft tissue injury, has reflected the pathological characters that local QI and blood meridian is impaired again." Prescriptions for Universal Relief is rolled over the wound door " speech " if roll over due to wound, interior moving grain, the road that blood is capable is improper to be led to, and the pain knot does not loose, and then is to swell to pain, controls and also removes the evil small house, makes qi and blood circulation, then can be also former." mean local channels damage blood oozing from the body openings or subcuta neous tissue arteries and veins and form hematoma or local stagnation of QI and blood outward, functional activity of QI being not smooth, qi and blood circulation is obstructed, dysfunction of the spleen in transportation and transformation, water-damp retention is local and cause swelling in limbs.When with the ruling by law of promoting the circulation of blood reducing swelling and alleviating pain it." Yizong Jinjian bonesetting heart method main idea " pointed out: " disease of traumatic injury is specially discussed from blood.The not broken and interior damage of skin the wounded has blood stasis more." disease of limb injury injures QI and blood more, the then stagnation of QI of feeling frustrated, blood trouble and blood stasis, the stagnation of QI can make blood stasis, and blood stasis is can choke capable, so that pathological changes is blood stasis, stagnates in flesh table livid purple swelling and ache then.Think that its essence is blood stasis, venation breakage after the damage, blood is from through forming the stasis of blood, the stasis of blood and heat-transformation.So the treatment general provisions are based on blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, clearing away heat and cooling blood.
The main Therapeutic Method of doctor trained in Western medicine has: braking, partial closure, physical therapy, anti-inflammation analgesis medicament etc., these methods also are not enough to control effectively the symptomatology that acute soft tissue injury produces.And anti-inflammation analgesia medicine drug side effect commonly used is bigger, takes the function that can influence many organs and system for a long time in a large number.And traditional Chinese medical science treatment in this respect has long history, outer treating method is many, though the Chinese patent medicine of some treatment soft tissue injurys is arranged, and these medicines all have certain curative effect, also have some problems, slow as some drug effect, flavour of a drug are more, are not easy to preparation and use, and effect is not fairly obvious, Time of Administration is long, curative effect instability etc.
Summary of the invention
The objective of the invention is at deficiency of the prior art, provide a kind of grieved arthralgia due to blood stasis for the treatment of soft tissue injury to loose.
One purpose more of the present invention is the application that provides a kind of grieved arthralgia due to blood stasis for the treatment of soft tissue injury to loose.
For achieving the above object, the technical scheme that the present invention takes is: a kind of grieved arthralgia due to blood stasis for the treatment of soft tissue injury looses, and it mainly is to be made by following bulk drugs that described grieved arthralgia due to blood stasis looses: Radix Et Rhizoma Rhei 400-600 part, Olibanum 400-600 part, Radix Notoginseng 400-600 part, Cortex cercis chinensis 725-925 part, Radix Angelicae Sinensis 650-850 part.
It mainly is to be made by following bulk drugs that described grieved arthralgia due to blood stasis looses: Radix Et Rhizoma Rhei 450-550 part, Olibanum 450-550 part, Radix Notoginseng 450-550 part, Cortex cercis chinensis 775-875 part, Radix Angelicae Sinensis 700-800 part.
It mainly is to be made by following bulk drugs that described grieved arthralgia due to blood stasis looses: 500 parts of Radix Et Rhizoma Rhei, 500 parts of Olibanums, 500 parts of Radix Notoginseng, 825 parts of Cortex cercis chinensiss, 750 parts of Radix Angelicae Sinensis.
Described grieved arthralgia due to blood stasis looses and also comprises: Herba Taraxaci 1150-1350 part, Myrrha 400-600 part.
Described grieved arthralgia due to blood stasis looses and also comprises: Herba Taraxaci 1200-1300 part, Myrrha 450-550 part.
Described grieved arthralgia due to blood stasis looses and also comprises: 1250 parts of Herba Taraxacis, 500 parts of Myrrhas.
For realizing above-mentioned second purpose, the technical scheme that the present invention takes is: described grieved arthralgia due to blood stasis is dispersed in the pain due to preparation treatment acute or chronic soft tissue injury, lumbar sprain, stiff neck, the gonarthromeningitis, the application in the swelling disease medicament.
The invention has the advantages that:
The diffusing compatibility of grieved arthralgia due to blood stasis of the present invention meets Chinese medicine " monarch " principle, through the pharmacodynamic experiment checking, has the effect of significant blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.Be applicable to pain, swelling due to acute or chronic soft tissue injury, lumbar sprain, stiff neck, the gonarthromeningitis.Toxic and side effects is little, and is evident in efficacy, uses safety, with low cost, easy to make, is suitable for life-time service, is easy to extensive popularization, is a kind of medicine for external use for the treatment of acute or chronic soft tissue injury safely and effectively.
The specific embodiment
Below in conjunction with embodiment the specific embodiment provided by the invention is elaborated.
Embodiment 1 grieved arthralgia due to blood stasis loose (one)
400 parts of Radix Et Rhizoma Rhei, 600 parts of Olibanums, 400 parts of Radix Notoginseng, 925 parts of Cortex cercis chinensiss, 650 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 2 grieved arthralgia due to blood stasis loose (two)
600 parts of Radix Et Rhizoma Rhei, 400 parts of Olibanums, 600 parts of Radix Notoginseng, 725 parts of Cortex cercis chinensiss, 850 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 3 grieved arthralgia due to blood stasis loose (three)
450 parts of Radix Et Rhizoma Rhei, 550 parts of Olibanums, 450 parts of Radix Notoginseng, 875 parts of Cortex cercis chinensiss, 700 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 4 grieved arthralgia due to blood stasis loose (four)
550 parts of Radix Et Rhizoma Rhei, 450 parts of Olibanums, 550 parts of Radix Notoginseng, 775 parts of Cortex cercis chinensiss, 800 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 5 grieved arthralgia due to blood stasis loose (five)
500 parts of Radix Et Rhizoma Rhei, 500 parts of Olibanums, 500 parts of Radix Notoginseng, 825 parts of Cortex cercis chinensiss, 750 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 6 grieved arthralgia due to blood stasis loose (six)
500 parts of Radix Et Rhizoma Rhei, 1250 parts of Herba Taraxacis, 500 parts of Olibanums, 500 parts of Myrrhas, 500 parts of Radix Notoginseng, 825 parts of Cortex cercis chinensiss, 750 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 7 grieved arthralgia due to blood stasis loose (seven)
400 parts of Radix Et Rhizoma Rhei, 1350 parts of Herba Taraxacis, 400 parts of Olibanums, 600 parts of Myrrhas, 400 parts of Radix Notoginseng, 925 parts of Cortex cercis chinensiss, 650 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
Embodiment 8 grieved arthralgia due to blood stasis loose (eight)
600 parts of Radix Et Rhizoma Rhei, 1150 parts of Herba Taraxacis, 600 parts of Olibanums, 400 parts of Myrrhas, 600 parts of Radix Notoginseng, 725 parts of Cortex cercis chinensiss, 850 parts of Radix Angelicae Sinensis.Employing traditional method preparation according to prescription flavour of a drug fine ground end altogether, transfers with water, maltose that to mix pasty state standby, during use prepared plaster is divided on kraft paper, with tissue sheet covering plaster surface, sticks at painful area during use.
The clinical trial that embodiment 9 grieved arthralgia due to blood stasis loose
One, materials and methods
(1) case is selected and grouping
Include standard in: meet acute soft tissue injury diagnostic criteria and Chinese medical discrimination; The course of disease is no more than 3 days persons; Age 18-55 year; Sex is regardless of; The signature Informed Consent Form; Estimate effect of the present invention for better, make this checking that comparability, objectivity more be arranged, with sprained ankle for going into the group standard.
Exclusion standard: do not meet the standard of including in; Gestation or women breast-feeding their children, allergic constitution or to this medicine allergy sufferers; Soft tissues such as fracture or muscle, tendon, ligament have fracture person fully; Be associated with serious primary disease such as cardiovascular, cerebrovascular, liver, kidney and hemopoietic system, serious systemic infection person, psychotic; The person that has the rheumatoid arthritis on inspection; Not medication in accordance with regulations can't be judged curative effect, or data is not congruent affects the treatment or safety judgement person.
Case grouping: (GCP) stipulate according to State Food and Drug Administration's " GCP ", by the requirement of new Chinese medicine I clinical trial phase, need to observe 100 examples altogether.To be selected in the patient and be divided into the grieved arthralgia due to blood stasis plaster group of loosing at random, the grieved arthralgia due to blood stasis two plaster groups of loosing, Vitalin Emulgel group, ointment for orthopedics group.
(2) Therapeutic Method
Grieved arthralgia due to blood stasis looses one group: adopt embodiment 5 described method preparations, stick at the swelling pain position, be advisable to cover whole diseased region.Changed dressings once every 24 hours, 1 week was 1 course for the treatment of, observed 2 courses for the treatment of.
Grieved arthralgia due to blood stasis looses two groups: adopt embodiment 6 described method preparations, stick at the swelling pain position, be advisable to cover whole diseased region.Changed dressings once every 24 hours, 1 week was 1 course for the treatment of, observed 2 courses for the treatment of.
The Vitalin Emulgel group: use Vitalin Emulgel, provided by Novartis Co.,Ltd, specification 20g/ props up, the approval number of the drug: the accurate word H19990291 of traditional Chinese medicines, evenly to smear at the swelling pain position, and every day 2-4 time, 1 week was 1 course for the treatment of, observed 2 courses for the treatment of.
Ointment for orthopedics group: according to the preparation of the described method of Chinese patent publication number CN100544752C: 20 parts of 50 parts of Rhizoma Drynariae, 50 parts of Boraxs, 50 parts of Sanguis Draxonis, 50 parts of Olibanums, 50 parts of Myrrhas, 60 parts of Radix Angelicae Sinensis, 55 parts of Radix Dipsaci, 55 parts of Pyritums, 50 parts of ground beetle, 50 parts of Radix Et Rhizoma Rhei, 35 parts of Radix Notoginseng, 35 parts of Herba Lycopodiis, 30 parts of Radix Clematidis and Herba speranskiae tuberculataes, decoct with Oleum sesami, filter and remove residue, the concentrated pellet (Plumbum preparatium) that adds gets plaster after releasing fire-toxin is handled.Changed dressings once every 24 hours, 1 week was 1 course for the treatment of, observed 2 courses for the treatment of.
(3) observation item
General data: sex, age, height, body weight, body temperature, resting heart rate, breathing, blood pressure etc.;
Lab index: anti-O, erythrocyte sedimentation rate, blood, urine routine test, liver, renal function etc.;
Health giving quality index: consider that major function of the present invention is pain relieving, detumescence, so be main parameters for observation on effect with signs such as pain, swelling, mobilities, adopt scoring mechanism method record.
A, pain intensity: 0 minute: painless; 1 minute: pain was light, can recognize, did not have a rest but do not influence routine work, can not wake up because of pain; 2 minutes: in the pain, but can stand, the slight effect routine work was had a rest; 3 minutes: pain was heavy, is out of patience, and had a strong impact on routine work and had a rest, because pain can not be fallen asleep.
B, swelling degree (comparing with strong side): 0 minute: no swelling; 1 minute: swelling was light, week footpath increase＜5%; 2 minutes: in the swelling, week footpath increase＞5%,＜10%; 3 minutes: swelling was heavy, week footpath increase＞10%.
C, mobility (comparing with strong side): 0 minute: activity freely; 1 minute: limitation of activity was light, and＜20%; 2 minutes: in the limitation of activity,＞20%,＜50%; 3 minutes: active receiving freight weight limit,＞50%.
D, ecchymosis degree: 1 minute: no ecchymosis; 2 minutes: the part was slightly livid purple, and area is less than 1 * 1cm; 3 minutes: local livid purple obvious, area was less than 4 * 4cm; 4 minutes: local livid purple obvious, area was greater than 4 * 4cm.
(4) observing time
A, each cardinal symptom, sign recorded once respectively at first day on-test, the 3rd day, first weekend, the tenth day, second weekend.
Each checks once and record before on-test and after finishing for b, safety indexes.
(5) therapeutic evaluation
Evaluation of clinical curative effect: according in the test to the scoring of pain, swelling, mobility, ecchymosis size, respectively and the overall improvement rate of calculating.Integration * 100% calculates the improvement rate before (integration before the treatment-treatment back integration)/treatment.Treatment back improvement rate 〉=90% is for curing; 70%～90% is produce effects; 30%～70% is produce effects;＜30% is invalid
Safety evaluatio: patient main suit's untoward reaction, lab index reach unusually dermoreaction by certainly relevant, probably relevant, may be relevant, may have nothing to do and irrelevant 5 grades of evaluation criterias evaluation certainly.With certainly relevant, probably relevant, may relevant three's joint account untoward reaction rate, the untoward reaction degree must specifically describe record (the researcher signature is also dated).When untoward reaction takes place, observe the doctor and can determine whether end test, the case of drug withdrawal should be carried out follow up survey to untoward reaction is arranged according to the state of an illness, recording processing process and result.
(6) statistical method
Carry out statistical procedures with the SPSS13.0 statistical package, relatively use paired t-test before and after the group internal therapy, measuring index between different groups adopts t check or the variance analysis of design in groups, and the counting index adopts chi-square criterion, and relation adopts correlational analysis method between the different test items.
Two, experimental result
1. four groups of baselines relatively
Pain degree, swelling degree, mobility, ecchymosis situation, age before each group patient treatment are compared, and four groups are not all had significant difference (P＞0.05), see Table 1.
Four groups of baselines of table 1 relatively
2. four groups of pain degrees relatively
Four groups relatively show, the diclofenac treatment got final product obvious alleviating pain in 3 days, and the diffusing two groups of treatments of grieved arthralgia due to blood stasis just can obviously reduce pain degree later in 7 days.Grieved arthralgia due to blood stasis looses and two looses one group with diclofenac group, ointment for orthopedics group and grieved arthralgia due to blood stasis treatment 14 days and to compare the equal significance of difference (P＜0.05), diffusing two curative effects of grieved arthralgia due to blood stasis were the most remarkable after two courses for the treatment of were treated in demonstration, and the diffusing one group of curative effect of ointment for orthopedics group and grieved arthralgia due to blood stasis is suitable substantially.Being excellent in early stage with diclofenac for the intervention degree of pain degree namely, secondly is that grieved arthralgia due to blood stasis looses two, grieved arthralgia due to blood stasis looses one, is ointment for orthopedics at last.The treatment later stage then is the diffusing two＞diclofenac of grieved arthralgia due to blood stasis＞diffusing one＞ointment for orthopedics of grieved arthralgia due to blood stasis successively.See Table 2.
Four groups of pain degrees of table 2 relatively
| Group | Before the treatment | Treated 3 days | Treated 7 days | Treated 10 days | Treated 14 days |
| Diffusing one (n=20) of grieved arthralgia due to blood stasis | 2.60±0.45 | 2.38±0.43 | 2.05±0.48* | 1.68±0.52*# | 0.33±0.29*# |
| Diffusing two (n=27) of grieved arthralgia due to blood stasis | 2.52±0.45 | 2.24±0.52* | 1.94±0.59* | 1.39±0.56* | 0* |
| Diclofenac (n=21) | 2.41±0.48 | 1.64±0.47*# | 0.80±0.37*# | 0.50±0.31*# | 0.32±0.29*# |
| Ointment for orthopedics (n=21) | 2.45±0.45 | 2.39±0.45 | 2.06±0.52* | 1.65±0.41*# | 0.38±0.32*# |
* with before the treatment compare difference statistical significance (P＜0.05) is arranged;
# and grieved arthralgia due to blood stasis loose two groups and compare difference statistical significance (P＜0.05) is arranged.
3. four groups of swelling degree relatively
Four groups relatively show, grieved arthralgia due to blood stasis looses two, grieved arthralgia due to blood stasis looses, and a treatment can obviously be alleviated swelling in 3 days, reduced the swelling degree, and compare difference before the treatment statistical significance (P＜0.05) is all arranged, and the diclofenac group is at treatment obvious alleviating pain after 7 days; Compare as seen between group, diffusing two curative effects of grieved arthralgia due to blood stasis are the most remarkable aspect the swelling alleviation, treating loose one group with diclofenac, ointment for orthopedics and grieved arthralgia due to blood stasis in 3,7,10 days compares difference statistical significance (P＜0.05) is all arranged, treat and compared difference with diclofenac in 14 days and still have statistical significance (P＜0.05), namely four groups of intervention degree for the swelling degree are grieved arthralgia due to blood stasis two＞grieved arthralgia due to blood stasis, the one＞ointment for orthopedics＞diclofenac that looses that looses successively.See Table 3.
Four groups of swelling degree of table 3 relatively
| Group | Before the treatment | Treated 3 days | Treated 7 days | Treated 10 days | Treated 14 days |
| Diffusing one (n=20) of grieved arthralgia due to blood stasis | 2.55±0.43 | 2.10±0.48*# | 1.78±0.50*# | 1.38±0.56*# | 0.48±0.47* |
| Diffusing two (n=27) of grieved arthralgia due to blood stasis | 2.52±0.43 | 1.72±0.53* | 0.98±0.63* | 0.48±0.40* | 0.26±0.25* |
| Diclofenac (n=21) | 2.30±0.40 | 2.16±0.36# | 1.89±0.43*# | 1.50±0.49*# | 0.68±0.42*# |
| Ointment for orthopedics (n=21) | 2.40±0.41 | 2.18±0.43# | 1.90±0.36*# | 1.49±0.58*# | 0.50±0.73*# |
* with before the treatment compare difference statistical significance (P＜0.05) is arranged;
# and grieved arthralgia due to blood stasis loose two groups and compare difference statistical significance (P＜0.05) is arranged.
4. four groups of mobilities relatively
Four groups relatively show, grieved arthralgia due to blood stasis looses two, grieved arthralgia due to blood stasis looses one, the ointment for orthopedics treatment can obviously improve mobility in 3 days, and compare difference before the treatment statistical significance (P＜0.05) is all arranged, and the diclofenac group can obviously improve mobility in treatment after 7 days; Compare as seen between group, diffusing two curative effects of grieved arthralgia due to blood stasis are the most remarkable aspect the raising mobility, treating loose one group with diclofenac, ointment for orthopedics and grieved arthralgia due to blood stasis in 3,7,10 days compares difference statistical significance (P＜0.05) is all arranged, treat and compared difference with diclofenac in 14 days and still have statistical significance (P＜0.05), namely four groups of intervention degree for mobility are the powder for dispersing blood stasis＞side of simplifying＞ointment for orthopedics＞diclofenac successively.See Table 4.
Four groups of mobilities of table 4 relatively
| Group | Before the treatment | Treated 3 days | Treated 7 days | Treated 10 days | Treated 14 days |
| Diffusing one (n=20) of grieved arthralgia due to blood stasis | 2.58±0.47 | 2.18±0.47*# | 1.93±0.34*# | 1.50±0.49*# | 0.43±0.37* |
| Diffusing two (n=27) of grieved arthralgia due to blood stasis | 2.52±0.43 | 1.72±0.45* | 0.96±0.55* | 0.48±0.43* | 0.30±0.29* |
| Diclofenac (n=21) | 2.64±0.41 | 2.45±0.41# | 1.95±0.48*# | 1.55±0.53*# | 0.75±0.46*# |
| Ointment for orthopedics (n=21) | 2.60±0.49 | 2.20±0.50*# | 1.95±0.42*# | 1.49±0.46*# | 0.49±0.51* |
* with before the treatment compare difference statistical significance (P＜0.05) is arranged;
# compares difference with the diffusing group of the silt that disappears statistical significance (P＜0.05).
5. four groups of ecchymosis degree relatively
Four groups relatively show, grieved arthralgia due to blood stasis looses two, grieved arthralgia due to blood stasis looses one, the ointment for orthopedics treatment can obviously be eliminated ecchymosis in 3 days, and compare difference before the treatment statistical significance (P＜0.05) is all arranged, and the diclofenac group can obviously be eliminated ecchymosis in treatment after 7 days; Compare as seen between group, diffusing two curative effects of grieved arthralgia due to blood stasis are the most remarkable aspect the elimination ecchymosis, treat and compared difference with the diclofenac group in 3,7,10 days statistical significance (P＜0.05) is all arranged, namely four groups of intervention degree for the ecchymosis degree are the powder for dispersing blood stasis＞side of simplifying＞ointment for orthopedics＞diclofenac successively.See Table 5.
Table 5 ecchymosis degree relatively
| Group | Before the treatment | Treated 3 days | Treated 7 days | Treated 10 days | Treated 14 days |
| Diffusing one (n=20) of grieved arthralgia due to blood stasis | 3.25±0.64 | 2.40±0.48* | 1.60±0.60* | 1.35±0.37* | 1.08±0.18* |
| Diffusing two (n=27) of grieved arthralgia due to blood stasis | 3.04±0.81 | 2.30±0.86* | 1.43±0.45* | 1.31±0.37* | 1.04±0.13* |
| Diclofenac (n=21) | 3.05±0.65 | 2.98±0.70# | 2.36±0.60*# | 1.80±0.48*# | 1.23±0.30* |
| Ointment for orthopedics (n=21) | 3.08±0.55 | 2.45±0.52* | 1.62±0.78* | 1.40±0.25* | 1.10±0.28* |
* with before the treatment compare difference statistical significance (P＜0.05) is arranged;
# compares difference with the diffusing group of the silt that disappears statistical significance (P＜0.05).
6. safety evaluatio
For guaranteeing drug safety, blood before and after the patient treatment, routine urinalysis, hepatic and renal function, anti-" O ", the every index of erythrocyte sedimentation rate are detected, every result is all in normal range before and after the treatment, though only there is the diffusing one group of ESR of grieved arthralgia due to blood stasis difference before and after treatment that statistical significance (P＜0.05) is arranged, but all in normal range, the patient does not have clinical malaise symptoms yet, so belong to normal difference, proves absolutely that four kinds of medicines all have higher clinical safety.See Table 6, table 7.
Blood, routine urinalysis are relatively before and after four groups of treatments of table 6
Hepatic and renal function, anti-" O ", erythrocyte sedimentation rate are relatively before and after four groups of treatments of table 7
* each group has statistical significance (P＜0.05) with treatment back comparing difference.
Three, conclusion
Result of study of the present invention shows, grieved arthralgia due to blood stasis looses two groups and compare the prognosis optimum with loose one group, ointment for orthopedics group of grieved arthralgia due to blood stasis with the diclofenac group aspect four of pain degrees, swelling degree, mobility, ecchymosis degree.Only diclofenac is very fast in treatment initial stage onset aspect pain degree, this may be because the Main Ingredients and Appearance of diclofenac is that non-steroidal anti-inflammatory analgesics thing diclofenac sodium is relevant, though and two onsets of loosing of grieved arthralgia due to blood stasis are slightly slow but stable curative effect finally still is higher than diclofenac lastingly, curative effect is not as good as diclofenac aspect pain relief for grieved arthralgia due to blood stasis diffusing, and other three aspects all are better than the diclofenac group.
Compare with diclofenac, though grieved arthralgia due to blood stasis loose one and grieved arthralgia due to blood stasis loose and two have the slightly slow stable curative effect of onset, toxic and side effects is little, compares with ointment for orthopedics, flavour of a drug number of the present invention still less, better efficacy, using clinically has better effect.
It is to make by monarch, minister, the combination principle helping, make that grieved arthralgia due to blood stasis of the present invention looses.Radix Et Rhizoma Rhei heat-clearing and toxic substances removing in the side, blood circulation promoting and blood stasis dispelling; Olibanum, Radix Notoginseng removing stasis to stop bleeding, the analgesic therapy detumescence; Cortex cercis chinensis promoting blood circulation and detoxication, removing heat from blood detumescence; The Radix Angelicae Sinensis regulating blood flow to alleviate pains.Analyzing Radix Et Rhizoma Rhei according to modern pharmacology has significant antiinflammatory and function of promoting blood circulation to disperse blood clots, and the boswellic acid compounds in the Olibanum is to have unique anti-inflammatory mechanisms, the non-steroidal plant antiinflammatory that untoward reaction is little; Radix Notoginseng then has good promoting blood circulation and hemostasis effect; Cortex cercis chinensis has anti-inflammatory and antalgic and to the spasmolysis of muscle, Radix Angelicae Sinensis has antithrombotic and changes hemorheological effect.Result of study of the present invention shows that the diffusing plaster treatment of grieved arthralgia due to blood stasis acute soft tissue injury is evident in efficacy, uses safety, and is with low cost, easy to make, is easy to extensive popularization, is a kind of medicine for external use for the treatment of acute soft tissue injury preferably.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (7)
1. a grieved arthralgia due to blood stasis for the treatment of soft tissue injury looses, it is characterized in that described grieved arthralgia due to blood stasis looses and made by following bulk drugs: Radix Et Rhizoma Rhei 400-600 part, Olibanum 400-600 part, Radix Notoginseng 400-600 part, Cortex cercis chinensis 725-925 part, Radix Angelicae Sinensis 650-850 part.
2. grieved arthralgia due to blood stasis according to claim 1 looses, it is characterized in that described grieved arthralgia due to blood stasis looses and made by following bulk drugs: Radix Et Rhizoma Rhei 450-550 part, Olibanum 450-550 part, Radix Notoginseng 450-550 part, Cortex cercis chinensis 775-875 part, Radix Angelicae Sinensis 700-800 part.
3. grieved arthralgia due to blood stasis according to claim 2 looses, and it is characterized in that, described grieved arthralgia due to blood stasis looses and made by following bulk drugs: 500 parts of Radix Et Rhizoma Rhei, 500 parts of Olibanums, 500 parts of Radix Notoginseng, 825 parts of Cortex cercis chinensiss, 750 parts of Radix Angelicae Sinensis.
4. a grieved arthralgia due to blood stasis for the treatment of soft tissue injury looses, it is characterized in that described grieved arthralgia due to blood stasis looses and made by following bulk drugs: Radix Et Rhizoma Rhei 400-600 part, Olibanum 400-600 part, Radix Notoginseng 400-600 part, Cortex cercis chinensis 725-925 part, Radix Angelicae Sinensis 650-850 part, Herba Taraxaci 1150-1350 part, Myrrha 400-600 part.
5. grieved arthralgia due to blood stasis according to claim 4 looses, it is characterized in that described grieved arthralgia due to blood stasis looses and made by following bulk drugs: Radix Et Rhizoma Rhei 450-550 part, Olibanum 450-550 part, Radix Notoginseng 450-550 part, Cortex cercis chinensis 775-875 part, Radix Angelicae Sinensis 700-800 part, Herba Taraxaci 1200-1300 part, Myrrha 450-550 part.
6. grieved arthralgia due to blood stasis according to claim 4 looses, it is characterized in that described grieved arthralgia due to blood stasis looses and made by following bulk drugs: 500 parts of Radix Et Rhizoma Rhei, 500 parts of Olibanums, 500 parts of Radix Notoginseng, 825 parts of Cortex cercis chinensiss, 750 parts of Radix Angelicae Sinensis, 1250 parts of Herba Taraxacis, 500 parts of Myrrhas.
7. be dispersed in the pain due to preparation treatment acute or chronic soft tissue injury, lumbar sprain, stiff neck, the gonarthromeningitis, the application in the swelling disease medicament according to the arbitrary described grieved arthralgia due to blood stasis of claim 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110273415 CN102302564B (en) | 2011-09-15 | 2011-09-15 | Pain stasis and paralysis eliminating powder for treating soft tissue injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110273415 CN102302564B (en) | 2011-09-15 | 2011-09-15 | Pain stasis and paralysis eliminating powder for treating soft tissue injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102302564A CN102302564A (en) | 2012-01-04 |
| CN102302564B true CN102302564B (en) | 2013-09-18 |
Family
ID=45376547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110273415 Expired - Fee Related CN102302564B (en) | 2011-09-15 | 2011-09-15 | Pain stasis and paralysis eliminating powder for treating soft tissue injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102302564B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107773716A (en) * | 2016-08-20 | 2018-03-09 | 张向阳中医诊所 | A kind of plaster for treating acute soft tissue injury |
| CN110538272A (en) * | 2019-09-11 | 2019-12-06 | 李松岭 | swelling-reducing and collateral-dredging powder for treating soft tissue injury and joint swelling and pain and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279080A (en) * | 2008-06-04 | 2008-10-08 | 金秀英 | Medicament composition for curing cervical vertebra disease, lumbar disease and traumatic injury and preparation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1120716C (en) * | 2000-09-02 | 2003-09-10 | 杨献志 | Plaster 'Gucixiao' and its preparing process |
| CN101062377B (en) * | 2007-06-01 | 2010-05-26 | 张瑞 | Adhesive plaster for diminishing inflammation, expelling wind and cold |
-
2011
- 2011-09-15 CN CN 201110273415 patent/CN102302564B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101279080A (en) * | 2008-06-04 | 2008-10-08 | 金秀英 | Medicament composition for curing cervical vertebra disease, lumbar disease and traumatic injury and preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102302564A (en) | 2012-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102302565B (en) | Stasis eliminating powder for treating soft tissue injury and cervical spondylosis | |
| CN110327403A (en) | A kind of Chinese medicine fuming-lotion that treating rheumatic arthralgia and its application method | |
| CN103690623B (en) | Medicated wine for treating traumatic injury | |
| CN102302564B (en) | Pain stasis and paralysis eliminating powder for treating soft tissue injury | |
| WO2012100754A1 (en) | Chinese medicine composition for treating stab wounds, burns, and various traumas | |
| CN102389561B (en) | Externally applied hot washing traditional Chinese medicinal composition for blood circulation invigorating and pain relieving and application thereof | |
| CN105168629A (en) | Traditional Chinese medicine gel for treating qi-stagnation and blood stasis type decubitus | |
| CN103142707A (en) | Traditional Chinese medicine paste or treating chronic soft tissue injury and preparation method thereof | |
| CN103705658B (en) | A kind of external traditional Chinese medicinal application for the treatment of rheumatoid arthritis | |
| CN101940652B (en) | Chinese medicinal liniment for treating psoriasis, multiple kinds of stubborn dermatitis and pruritus | |
| CN104147174A (en) | Medicament for treating stroke | |
| CN104257967B (en) | A kind of Chinese medicine for treating injury gained in sports | |
| CN104815090B (en) | A kind of external preparation and preparation method thereof for treating closed injury | |
| CN103585294A (en) | Plaster for treating osteoproliferation and preparation method of plaster | |
| CN115154504B (en) | Traditional Chinese medicine composition for treating yang deficiency and blood stasis type gonarthritis as well as preparation method and application thereof | |
| CN110302271B (en) | Cape jasmine capable of dispelling cold and preparation method thereof | |
| CN102225125B (en) | Externally applied traditional Chinese medicine composite for treating joint pain caused by rheumatoid arthritis and preparation method thereof | |
| CN110420305B (en) | Traditional Chinese medicine composition for treating chronic muscle injuries and preparation method thereof | |
| CN116036168B (en) | Traditional Chinese medicine composition for treating phlebitis and application thereof | |
| CN102579623A (en) | Preparation method of Chinese lotion for treating traumatic type ecthyma | |
| CN102205018B (en) | Traditional Chinese medicinal lotion for treating abdominal wall fascitis | |
| CN105381089A (en) | Traditional Chinese medicine lotion for treating skin itch of uremia patient and nursing method | |
| CN104474517A (en) | Chinese patent medicine for treating cervical syndrome and preparation method | |
| CN106539910B (en) | Traditional Chinese medicine composition containing radix aconiti and application thereof | |
| CN105193974B (en) | A kind of Chinese medicine composition that treating bone fracture disease and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |